目的 探讨川芎嗪注射液联合拉贝洛尔治疗妊娠期高血压的临床效果。方法 选取兴宁市妇幼保健院2015年3月-2016年12月收治的妊娠期高血压患者98例，随机分为对照组与治疗组，每组各49例。对照组患者静脉滴注盐酸拉贝洛尔注射液，50 mg加入5%葡萄糖溶液250 mL中，1次/d。治疗组患者在对照组的基础上静脉滴注盐酸川芎嗪注射液，120 mg加入5%葡萄糖溶液250 mL，1次/d。两组患者均治疗10 d。评价两组患者临床疗效，同时比较治疗前后两组患者血压、血浆黏度、24 h蛋白尿定量、尿素氮（BUN）、尿微量清蛋白（MA）、超敏C反应蛋白（hs-CRP）和同型半胱氨酸（Hcy）水平变化情况。结果 治疗后，对照组和治疗组总有效率分别为79.59%、93.88%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者舒张压和收缩压均明显下降（P<0.05）；且治疗组患者的血压水平明显优于对照组（P<0.05）。治疗后，两组患者血浆黏度、24 h蛋白尿定量和MA水平均明显降低（P<0.05）；且治疗组患者上述观察指标水平明显低于对照组（P<0.05）。治疗后，两组患者血清hs-CRP和Hcy水平均显著降低（P<0.05）；且治疗组患者hs-CRP与Hcy水平显著低于对照组（P<0.05）。结论 川芎嗪联合拉贝洛尔治疗妊娠期高血压疗效显著，且具有较高的安全性，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy and safety of Ligustrazine Hydrochloride Injection combined with labetalol in treatment of gestational hypertension. Methods Patients (98 cases) with gestational hypertension in Xingning Maternal and Child Health Care Hospital from March 2015 to December 2016 were randomly divided into control and treatment groups, and each group had 49 cases. Patients in the control group were iv administered with Labetalol Hydrochloride Injection, 50 mg added into 5% glucose injection 250 mL, once daily. Patients in the treatment group were iv administered with Ligustrazine Hydrochloride Injection on the basis of the control group, 120 mg added into 5% glucose injection 250 mL, once daily. Patients in two groups were treated for 10 d. After treatment, the clinical efficacy was evaluated, and the changes of blood pressure, plasma viscosity, 24 h urinary protein, BUN, MA, hs-CRP and Hcy levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 79.59% and 93.88%, respectively, and there were differences between two groups (P<0.05). After treatment, the diastolic and systolic blood pressure in two groups was significantly decreased (P<0.05). And the blood pressure level in the treatment group was obviously better than that in the control group (P<0.05). After treatment, the plasma viscosity, 24 h urinary protein, and MA levels in two groups were significantly decreased (P<0.05). And these index levels in the treatment group were obviously lower than those in the control group (P<0.05). After treatment, hs-CRP and Hcy levels in two groups were significantly decreased (P<0.05). And the hs-CRP and Hcy levels in the treatment group were obviously lower than those in the control group (P<0.05). Conclusion Ligustrazine Hydrochloride Injection combined with labetalol has significant curative effect in treatment of gestational hypertension with high security, which has a certain clinical application value.